Product Images Aripiprazole

ARIPiprazole is a prescription medication and its NDC number is 70518-3380-01. It has been manufactured by Amneal Pharma in Ahmedabad, India. The lot number and expiration date of the medication are missing. The medication should be stored at a temperature range of 20-26°C with excursions permitted to 15-30°C. The packaging suggests keeping medication out of reach of children. The directions for use can be found in the package insert. The medication has been repackaged by RemedyRepack Inc in Indiana.*

This is a medication called Aripiprazole which is available only with a prescription. The package contains 3380-00 NDC number, the manufacturing details of the medicine, and an expiry date with the LOT number. The medicine should be stored between 20-26°C and should be kept out of the reach of children. The package insert contains directions for use. Additionally, the medicine has been repackaged by RemedyRepack Inc., Indiana.*

This text provides information on the potential effect of several drugs on Aripiprazole, including Ketoconazole, Y206 Inhibitor, Carbamazepine, Gastric Acid Blockers such as Famotidine, and other drugs such as Valproate, Hum Auc, and Lorazepam. The graph shows fold change and the percentage of change relative to the reference without interacting drugs.*

This text appears to be a chart or table showing the effect of the drug Aripiprazole on other drugs. It includes various medication names such as dextromethorphan, warfarin, omeprazole, valproate, lithium, lorazepam, and escitalopram. It also references enzymes such as CYP2D6 B and UGT1A4. The chart appears to show "Fold Change" and "90% I" related to the effect of aripiprazole on the other drugs listed, with a relative change up to 20. It is unclear what the specific values represent without further context.*

The text provides information on different special populations such as poor versus extensive metabolizers, gender (male versus female), and age (1864 versus 265 years old). It also includes different levels of hepatic impairment (mild, moderate, and severe) and severe renal impairment. The last part of the text seems to display a graph related to PK (pharmacokinetics) of Avipiprazole and fold change with respective 90% CI.*

This appears to be a graph or table comparing the proportion of relapse between two groups (Avipiprazole and Placebo) over the course of time (in days from randomization). The data is presented in a numerical format with values ranging from 0 to 182.*